Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SRScholar Rock Holding Corporation logo

Scholar Rock Holding Corporation (SRRK)

NASDAQ Global Select · Currency in USD
$41.49 ▼ -0.47 (-1.12%)
At close: Oct 23, 4:00 PM ET. Market closed.
$41.06 ▼ -0.43 (-1.04%)
After hours: Oct 23, 7:51 PM ET

Summary

Previous Close
$41.96
Open
$41.58
Day's Range
$40.76 – $41.88
52 Week Range
$27.07 – $61.76
Volume
1,206,859
Avg. Volume
1,663,096
Market Cap
$5.05B
Beta (5Y Monthly)
0.62
PE Ratio (TTM)
--
EPS (TTM)
-$3.13
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$71.30

Profile: Scholar Rock Holding Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
289
CEO
David L. Hallal

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate -$0.85 · Revenue est. $303.93K
DateEst.Actual
Aug 6, 2026-$0.84-$0.84Beat
May 7, 2026-$0.82-$0.83Miss
Mar 3, 2026-$0.88-$0.88Beat
Nov 14, 2025-$0.84-$0.90Miss
Aug 6, 2025-$0.66-$0.98Miss
May 14, 2025-$0.63-$0.67Miss

Analyst view

Consensus price target
$71.30 ▲ +71.8%
Range $58.00 – $84.00
Rating: Buy
Buy 93% · Hold 7% · Sell -0%

Get free alerts on SRRK and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.